New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
07:55 EDTNVDQNovadaq price target raised to $26 from $23 at Canaccord
Canaccord raised its price target on Novadaq calling it the most compelling growth story in med-tech because it possesses one of the largest TAM opportunities in their group. The firm expects the company to re-acquire US marketing rights for SPY Elite in 2015 and then go direct thereafter resulting in higher average selling prices. Shares are Buy rated.
News For NVDQ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2015
10:00 EDTNVDQOn The Fly: Analyst Initiation Summary
Subscribe for More Information
October 7, 2015
18:27 EDTNVDQNovadaq initiated with an Outperform at Wedbush
Subscribe for More Information
October 2, 2015
07:51 EDTNVDQNovadaq shares at attractive levels again, says Canaccord
Subscribe for More Information
October 1, 2015
07:18 EDTNVDQNovadaq, Arthrex announce co-marketing agreement for PINPOINT
Novadaq Technologies announced that it has entered into a Co-Marketing Agreement with Arthrex. The Agreement allows the two companies to combine their expertise and devices to offer a world-class endoscopic system for a wide variety of surgical specialties, including orthopaedic, general, colorectal and gynecological surgeries. NOVADAQ's "plug and play" PINPOINT upgrade kit facilitates the seamless integration of its SPY imaging technology into Arthrex's Synergy System, combining the most clinically relevant fluorescence imaging experience with the leading 4K white light endoscopic system. Both companies will continue to sell their own standalone systems in addition to the combined systems, giving end-users unparalleled choice in providing the best care for their patients. Arthrex will have the ability to include the PINPOINT upgrade kit in all new Synergy System purchases, as well as upgrade their existing installed base. NOVADAQ's sales team will continue to sell PINPOINT as a part of its fluorescence imaging ecosystem and NOVADAQ will also supply the disposable kits required to perform SPY imaging procedures directly to those Arthrex customers that have purchased PINPOINT upgrade kits.
September 29, 2015
05:59 EDTNVDQNovadaq pullback brings buying opportunity, says Piper Jaffray
After attending the company's iSPIES meeting in Las Vegas, Piper Jaffray analyst Matt O'Brien says Novadaq's business momentum "remains strong." He continues to believe that competitive concerns are overblown and thinks the company should meet or beat Q3 estimates. The analyst views the recent pullback in shares as a buying opportunity and reiterates an Overweight rating on Novadaq with a $16.50 price target.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use